On March 22, 2022 Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), reported that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City (Press release, Coherus Biosciences, MAR 22, 2022, View Source [SID1234610574]). Coherus executives and scientists will provide updates on the preparation for multiple potential new product launches anticipated over the next 15 months as well as the Company’s transformational entry into immuno-oncology with PD-1 inhibitor toripalimab and innovative PD-1 combination candidates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and analysts who would like to attend the Coherus Analyst Day event in-person or virtually may pre-register here.

A live webcast of the Analyst Day will be available on the Events & Presentations page of the Coherus website at View Source Please access the website prior to the start of the event to ensure a timely connection to the webcast. A replay of the event will be archived on the Coherus website for 30 days.